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Abstract
Background: A position paper based on the collective experiences of Argus II Retinal Prosthesis System
investigators to review strategies to optimize outcomes in patients with retinitis pigmentosa undergoing retinal
prosthesis implantation.
Methods: Retinal surgeons, device programmers, and rehabilitation specialists from Europe, Canada, Middle East,
and the United States were convened to the first international Argus II Investigator Meeting held in Ann Arbor, MI
in March 2015. The recommendations from the collective experiences were collected. Factors associated with
successful outcomes were determined.
Results: Factors leading to successful outcomes begin with appropriate patient selection, expectation counseling,
and preoperative retinal assessment. Challenges to surgical implantation include presence of staphyloma and
inadequate Tenon’s capsule or conjunctiva. Modified surgical technique may reduce risks of complications such as
hypotony and conjunctival erosion. Rehabilitation efforts and correlation with validated outcome measures
following implantation are critical.
Conclusions: Bringing together Argus II investigators allowed the identification of strategies to optimize patient
outcomes. Establishing an on-line collaborative network will foster coordinated research efforts to advance
outcome assessment and rehabilitation strategies.
Background
Retinitis pigmentosa (RP) is a heterogeneous group of
inherited retinal diseases affecting over one million indi-
viduals worldwide with an estimated prevalence of 1 in
4000 [1]. Though RP can be caused by mutations in any
of over 190 genes, all lead to degeneration of the photo-
receptor layer of the retina [2]. The relative preservation
of inner retina has led to efforts to develop retinal pros-
theses to stimulate residual surviving tissue.
The Argus II Retinal Prosthesis System (Second Sight
Medical Products, Inc., Sylmar, CA, USA) is a surgically
implantable device designed to provide artificial vision
to patients with outer retinal degenerative disease such
as RP. It consists of an external video-processing unit
that translates visual information from an eyeglass-
mounted video camera into electrical signals. The im-
planted portion consists of a receiver coil that sends the
electrical stimulus via a polymerized cable to a 60-
electrode array that is implanted onto the retinal surface.
Electrical stimulation of remaining retinal neurons
evokes action potentials that travel through the optic
nerve to the brain and elicit visual percepts. The device
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has been implanted in over 100 patients worldwide since
receiving commercial approval in the European Union
(CE Mark) in March 2011 and by the US Food and Drug
Administration (FDA) in February 2013 [3]. The implant
received medical device license approval by Health
Canada in December 2014. In Saudi Arabia, it first re-
ceived limited approval (restricted to the King Khaled
Eye Specialist Hospital, Riyadh) in June 2012 and full ap-
proval in June 2015. Studies have shown promising re-
sults with visual function as well as improved
performance on orientation and mobility tasks [4–8].
Longer-term studies have shown that the implant re-
mains safe, and positive visual results can be sustained
beyond 5 years of chronic use [9].
Since the Argus II prosthesis represents a novel para-
digm for treatment of retinal disease, multidisciplinary
review of early experiences is critical in recognizing po-
tential challenges and refining current practices. The
purpose of this manuscript is to summarize the recom-
mendations to optimize patient outcomes with the
Argus II device by analyzing the collective experience of
investigators.
Methods
The first international investigators’ meeting of retinal
surgeons, device programmers, and rehabilitation spe-
cialists was convened in Ann Arbor, Michigan, USA in
March 2015. The aim of the meeting was to share col-
lective experiences with patient selection, surgical tech-
nique, outcome assessment, device programming issues,
rehabilitation challenges, and future directions. Partici-
pants were asked to share factors contributing to opti-
mal surgical outcomes; success with fitting, assessment,
and rehabilitation; and patient satisfaction. This manu-
script is a report of these collective experiences and rec-
ommendations to optimize patient outcomes with the
Argus II system.
Results and Discussion
Patient selection
Retinal device implantation represents a significant in-
vestment from both healthcare payers as well as the pa-
tients themselves. While one study found Argus II to be
a cost-effective intervention for RP patients compared to
usual care, the device and implantation are associated
with high initial costs [10]. In addition, frequent follow-
up examinations and dedicated compliance with re-
habilitation represent significant patient commitment.
Patient selection begins with a screening process typic-
ally conducted by low vision specialists and non-physician
support staff. Since Argus II is currently only approved for
subjects with profound RP, excluding patients with rela-
tively good vision and incompatible diagnoses is important
in reducing unnecessary examinations. The typical patient
selection process involves a minimum of two clinical
visits. Investigators recommend a full ophthalmologic
evaluation including accurate documentation of visual
function and anatomical assessment to determine factors
that may affect successful implantation. Anterior segment
evaluation should include notation of conjunctival or
scleral thinning and phakic status. Dilated fundus examin-
ation encompasses documentation of any optic disc cup-
ping, posterior vitreous detachment (PVD) status,
presence of macular scar, posterior staphyloma, epiretinal
membrane, and retinal breaks.
Ancillary testing includes optical coherence tomog-
raphy and ocular ultrasonography looking for anatomic
changes such as staphyloma or epiretinal membrane that
may interfere with device placement. Additional pre-
operative clinical visits include evaluation for general
anesthesia readiness, review of consent forms, introduc-
tion to post-operative rehabilitation services, and coun-
seling sessions to manage expectations.
The investigators identified the management of patient
expectations as a critical component of the patient selec-
tion process. Counseling of patient expectations begins
with the initial phone screening and continues through
the post-operative period. Patients should be advised
that the output from the device should be interpreted as
an entirely new type of visual sensation rather than an
attempt to restore previous vision. Most investigators
felt that potential candidates could benefit from talking
with selected past recipients of the device. Since family
support throughout the pre-operative and post-operative
is important, family members should be included in ex-
pectation counseling. Parallel conclusions can be drawn
from experiences with pediatric cochlear implantation
for hearing in which greatest success is achieved when
the outcome matches or exceeds pre-operative expecta-
tions of the well-counseled family [11, 12]. Rehabilitation
specialists strongly concur that past experiences with
low vision and blindness rehabilitation, and emphasis on
the importance of therapy prior to implantation is help-
ful in preparing patients for the significant commitment
required after surgery. The investigators identified the
following characteristics to be positively correlated with
good outcome: reasonable expectations, supportive fam-
ily members, existing blindness skills, patient familiarity
with accessible technology for low vision and blindness,
patient’s baseline functional abilities including general
health, communication, and cognition.
Refining the criteria for patient selection in terms of
the effect of patient age, presence of posterior staphy-
loma, and presence of severe outer retinal macular de-
generation is still debated. A Phase 1 clinical trial is
underway in Manchester, UK evaluating the feasibility of
Argus II in severe dry age-related macular degeneration
(AMD)/geographic atrophy [13]. There is ongoing
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investigation about factors that affect outcomes, includ-
ing age. Investigators in Saudi Arabia and the
Netherlands have examined the anatomical and func-
tional outcome of patients less than 50 years old under-
going Argus II implantation. It has been hypothesized
that younger patients have more preservation of the
inner retinal layers, which could lead to better outcomes,
but further research needs to be done.
Patients with abnormal posterior curvature of the eye
such as staphyloma may not be ideal candidates for im-
plantation since optimal signal transduction from the
electrode array to the target cells requires good contact
with the retinal surface. In vitro and in vivo studies have
shown that retina-electrode distance significantly affects
perceptual thresholds [14–16]. Proper centering of the
array over the macula and creating close contact be-
tween the electrodes and retinal surface were identified
as common challenges in implantation. Compression
and puckering of the retina at the rim of the staphyloma,
known as “snowplowing,” with resulting cystoid macular
edema has also been observed by one investigator. De-
formational force on the retina may cause cystoid macu-
lar edema in a manner similar to tractional forces
causing vascular leakage and macular edema from con-
ditions such as epiretinal membrane or vitreomacular
traction. This phenomenon has been reported in one
Argus II patient with staphyloma, but could conceivably
arise in other conditions with abnormal posterior retinal
curvature such as long axial length. Overall, retinal
thickening with cystoid macular edema from all causes
is not common and seen in less than 5 % of patients
[17]. While some patients with less than ideal apposition
have been pleased with their results, significant retina-
array distance in staphyloma has also resulted in reduced
sensitivity to electrical stimulation and in some cases
electrophosphenes could not be generated at any stimu-
lation level. A second retinal tack has been used to im-
prove suboptimal array positioning. Alternatively, the
renewed interest and successful outcomes of macular
buckling for myopic traction maculopathy suggest a pos-
sible use for this technique in patients with staphyloma
considering Argus implantation. The use of macular
buckling or scleral slings, while not previously attempted
in Argus patients, was discussed as a conceivable option
to improve array apposition.
The Argus II directly stimulates the inner retina, and
evidence of intact inner retinal function must be con-
firmed prior to implantation, particularly in patients
with no light perception. This is typically performed
with the dark-adapted photo flash test. In rare instances,
when no conclusive determination of light perception is
obtained with the photo-flash test, integrity of the optic
nerve can be tested through Burian Allen contact lens
electrical stimulation of the whole globe using a
Digitimer D185 stimulator (Digitimer Ltd, Welwyn Gar-
den City, United Kingdom) or similar instrument. Since
some patients with certain types of RP have been shown
to have corresponding inner retinal laminar abnormal-
ities from retinal remodeling, optical coherence tomog-
raphy (OCT) segmentation may have a role in patient
selection [18]. Currently, OCT only provides informa-
tion about inner retinal structure, and additional study is
needed to determine how structure determines function
in RP patients. In regards to outer retinal changes, some
investigators have found poor implant functioning in
some patients with severe outer retinal degeneration.
Despite some cases of poor electrode functioning, pa-
tients can continue to show improved mobility and func-
tional performance in the home environment using the
Argus device. At present, pre-operative OCT is only
used to identify staphyloma and epiretinal membranes
that may affect implantation. Further study, however, is
needed to investigate whether inner and outer retinal
segmentation by OCT can be used to aid patient selec-
tion. Investigators note that part of the limitation is diffi-
culties in obtaining adequate quality OCT scans due to
lack of fixation and nystagmus. Efforts can be made to
improve scans in these patients with coaching, patience,
use of a Thornton ring, or in exceptional cases by per-
forming a retrobulbar block.
Surgical technique
Implanting the Argus II retinal prosthesis represents a
new era in vitreoretinal surgery and with this comes a
new set of challenges. The creation of this unique
“silico-biologic” interface represents a refinement of sev-
eral techniques already familiar to vitreoretinal surgeons.
If the patient is phakic, phacoemulsification with or
without an intraocular lens (IOL) implantation should
be performed one month prior or as a combined proced-
ure with Argus II implantation. A 360° conjunctival
peritomy is performed followed by isolation of the 4
recti muscles. The encircling band of the extraocular
portion of the device is secured in a fashion similar to a
scleral buckle. The electronics case and implant coil are
carefully positioned in the superotemporal quadrant ac-
cording to axial length-related tables and are sutured to
the sclera through tabs located on the band. The investi-
gators have identified this step as a critical component
of the surgery since precisely measured external fixation
is necessary for optimal positioning of the electrode
array over the macula. Next, a 3-port pars plana vitrec-
tomy with shave of peripheral vitreous is performed.
The array and array cable is inserted through a 5.2 mm
sclerotomy and secured to the retina-choroid-sclera with
a custom-made titanium retinal tack.
Care must be taken throughout the procedure in
handling the delicate electronics using only silicone
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tipped forceps. A patch graft is used to cover the suture
tabs and the cable, and complete closure of the conjunc-
tiva is critical. Standard postoperative steroid and anti-
biotic eye drops are administered and typical
postoperative follow-up is indicated to monitor for ad-
verse events.
Adverse events
Surgery-associated adverse events including conjunctival
erosion/dehiscence, hypotony, and endophthalmitis were
found in 23, 13, and 10 % of patients, respectively, in the
3-year results of the Argus II trial [17]. An improved ad-
verse event profile has since been reported following re-
finement of the procedure and device itself [19].
Nonetheless, retinal surgeons at the investigators meet-
ing identified conjunctival erosion and hypotony as the
most common surgical complications of implantation.
Hypotony following Argus II implantation typically
arises from inadequate closure of sclerotomies, but less
commonly may be due to damage to the ciliary body.
Vigilant attention to closure, especially the superotem-
poral sclerotomy around the array cable, is critical. Scler-
otomy closure is facilitated by proper initial wound
construction. The sclerotomy for the array cable should
be straight as opposed to a chevron or curved shape,
which may cause cable and wound puckering. It should
also be directed perpendicular to the sclera in order to
prevent ciliary body detachment during insertion of the
array into the vitreous cavity. During closure, mattress
sutures with long scleral passes increase vector forces in
re-apposing wound edges. The sutured wound should be
dried and thoroughly checked for leakage. It should not
be assumed that small amounts of oozing from the
wound will resolve spontaneously. Other techniques
which have been attempted, but where consensus re-
garding effectiveness has not been reached, include
fluid-air exchange to increase vitreous plugging of the
wound, partial thickness scleral flaps akin to trabeculect-
omy surgery, and the use of sealants such as corneal gel
sealant or fibrin glue. When post-operative hypotony oc-
curs, investigators agree that a short period of close
follow-up with pressure patching can be sufficient if no
other serious adverse signs are present. It is likely, how-
ever, that the patient may require reopening of the con-
junctival/pericardial graft with further inspection and
suturing of the sclerotomy. Persistent hypotony or other
complications such as enlarging choroidal detachments
and anterior chamber flattening should prompt return
to the operating room for wound revision.
Conjunctival erosion is a second commonly identified
complication of Argus II implantation and typically oc-
curs over the raised profile of suture tabs. Several tech-
niques were suggested to reduce the risk of this
complication. The array cable and the anterior edge of
the coil should be covered with processed pericardium
or donor corneal graft. The manufacturer recommends
Tenon’s membrane closure prior to conjunctival closure.
Nylon suture is also preferred as the braided nature of
Mersilene polyester sutures may contribute to erosion.
Rotating knots posteriorly underneath suture tabs and
leaving suture tails long may help with a lower profile
knot that has a decreased risk of eroding conjunctiva. If
conjunctival erosion is discovered post-operatively, top-
ical antibiotics should be used until the patient can re-
turn to the operating room for closure. Wound revision
should include adequately opening the area of eroded
conjunctiva, thoroughly releasing any areas of traction,
debriding or cauterizing areas of epithelialization, and
re-covering exposed areas with pericardium or grafted
conjunctiva. If the coil is well encapsulated and secure,
some investigators suggest cutting off the suture tab.
Other less common complications associated with Argus
II implantation include retinal detachment and endophthal-
mitis. To reduce the risk of retinal detachment, several sur-
geons recommended that triamcinolone acetonide be used
to perform better shaving of the vitreous base in both the
superotemporal and inferotemporal quadrants where the
array and the tack, respectively, will be inserted. Since the
vitreous cortex is very adherent in patients with RP, the
hyaloid frequently cannot be detached anterior to the mid-
periphery and excessive traction on the retina should be
avoided. Similarly, macular epiretinal membranes should be
peeled to improve contact between the electrodes and the
retina. All agreed, however, that internal limiting membrane
peeling is unnecessary and increases the risk of retinal holes
in the macula. The investigators do not recommend
prophylactic 360° laser retinopexy to the periphery. In cases
of retinal tears or localized detachments observed post-
operatively, laser retinopexy has been successfully used
away from the array without change in electrode function.
As in all intraocular surgeries, infectious endophthalmitis is
a rare but potential devastating complication in Argus II
implanted patients. With a high degree of suspicion and
early treatment with intravitreal antibiotics, all cases of en-
dophthalmitis in Argus II patients to date have been suc-
cessfully resolved without the need to explant the device.
The incidence of adverse events continues to be equal
to or lower than those reported in pre-market studies
and in studies of glaucoma drainage devices [20]. Never-
theless, investigators suggest that patients should be ed-
ucated about potential signs and symptoms of post-
operative complications such as endophthalmitis and
conjunctival erosion, as early detection is the key to
maintaining successful outcomes.
Device programming
Following surgical implantation, the Argus II device is
fitted, or programmed, before the camera can be turned
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on. The aim of the first session is to gain an understand-
ing of which electrodes on the array will be used, by first
disabling individual electrodes whose resistance values
are too high, and then performing a quick array scan to
determine which electrodes on the array reliably yield
percepts, or phosphenes, at different stimulation ampli-
tudes. The second session involves measuring the per-
ceptual threshold (i.e. the minimum current required to
produce a percept the patient can see 50 % of the time)
for electrodes that yielded a percept during array scan-
ning. A video configuration file (VCF) is generated that
defines how the video signal from the camera is mapped
to the electrical signal for individual or groups of elec-
trodes, and determines how many electrodes are stimu-
lated simultaneously and at what frequency. Different
image processing filters and VCF configurations are
saved onto the patient’s VPU for use in different condi-
tions: normal light conditions, contrast enhancement for
low light conditions, and a setting for edge detection.
The last programming step before turning the camera
on compensates for the angle at which the array is
placed on the retina during surgery.
Device programming can be an ongoing process as
changes to either the array or a patient’s responses to elec-
trode stimulation can occur. It is not uncommon for a pa-
tient to require several troubleshooting sessions to optimize
the function of the device. Some challenges encountered to
date include: decreasing sensitivity with ongoing stimula-
tion, changes in perceptual thresholds, interference from
spontaneous phosphenes, short duration of percepts, high
thresholds or lack of thresholds, inadequate contrast,
blurred contours/edges, poor alignment, inadequate radio
frequency link between the glasses and the implant, over-
heating of the coil on the glasses, difficult battery insertion,
poor eyeglass fit, and discomfort during stimulation. Post-
surgical complications can also interfere with the program-
ming process. Many of these challenges, however, can be
remedied by an experienced programmer.
Some of the programming issues identified by investiga-
tors may be mitigated by the development of new program-
ming software (the “Programming Assistant”) designed to
streamline the programming process. This new software is
intended to be more intuitive, to measure general sensitivity
rather than specific thresholds, to simplify the camera
alignment process, and to determine comfort under more
real-world stimulation conditions. The aim is to reduce the
programming time from 8 to 10 h, to 2 h or less. The new
Programming Assistant will be tested in a small clinical
trial, and if patient performance is not negatively impacted,
approval will be sought to release the software in all mar-
kets. The glasses are also being redesigned for improved
comfort.
To address other challenges encountered during the
programming process, investigators had several
suggestions. These included: a) Postponing the program-
ming process until any surgical complications are re-
solved; b) Grouping electrodes together into groups of
four (quads) or greater when percepts are not present
after stimulating individual electrodes; c) Devising strat-
egies to better counsel patients and their families regard-
ing expectations for how their vision will change after
device implantation. One center is developing a vision
simulator to help families and rehabilitation specialists
understand what a patient might experience with the
Argus II system turned on; d) Implementing cross-
training of the device programming and low vision re-
habilitation teams so they can work together to improve
the programming process; e) Offering targeted low vi-
sion rehabilitation to improve patient performance and
satisfaction; f ) Increasing our understanding of glare
complaints by measuring photosensitivity and light
perception.
Outcome assessment
One striking, and perhaps unexpected, observation was
that some performance measures, and especially per-
formance of more complex, real-world tasks, did not ne-
cessarily correlate with a patient’s thresholds. In other
words, having more electrodes with lower thresholds did
not always translate to a better visual outcome or higher
patient satisfaction, and patients with very different
threshold levels (i.e. tending towards very high versus
very low) can still have similar functional performance.
This observation suggests it will be difficult to predict
functional outcomes based on threshold levels alone.
There is currently no standardized measure to assess
functional outcomes in patients with ultra-low vision.
Because profound vision loss precludes conventional as-
sessment of visual acuity, custom end-points were de-
signed to measure functional outcomes for the Argus II
clinical trial patients. Visual acuity was measured by
three methods: grating visual acuity, square localization,
and direction of motion [21]. Functional vision was eval-
uated with a “door task” and “line task.” Following dis-
cussions with FDA, the Functional Low-Vision Observer
Rated Assessment (FLORA) was developed in response
to an identified lack of qualified outcome measures to
measure impacts on quality of life. However, this test
may have limited utility as a standardized outcome
measure due to its complexity and its reporting of sub-
jective measures that are difficult to quantify [22]. A
promising alternative for assessing outcomes and func-
tional gains for Argus II patients is the Prosthetic Low
Vision Rehab (PLoVR) questionnaire that was developed
specifically for patients with ultra-low vision [23]. Diffi-
culty ratings for a list of approximately 150 items/tasks
relying on high/low contrast, lighting conditions, or
form/movement were collected from ultra-low vision
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survey respondents and used to generate a logit scale
where person ability and difficulty measures are plotted.
This scale can then be used to measure changes in an
individual’s visual ability over time. An adaptive version
of the questionnaire has been recently developed and is
being further refined [24].
Rehabilitation challenges
Implantation of the Argus II into the eyes of patients
with only bare or no light perception gives them access
to a new visual input that needs to be integrated with
any residual vision they possess, as well the low-vision
and blindness skills they had previously developed. Re-
habilitation aims to facilitate this integration in order to
enhance quality of life and independence. The rehabilita-
tion process consists of two major components: in-clinic
rehabilitation and community rehabilitation. In the
clinic, patients are taught the components of the Argus
II system, how to manipulate the controls, as well as
basic visual skills. Community-based rehabilitation is fo-
cused on visual integration into functional activities of
daily living and refining existing blindness skills.
The Instructional kit provided by Second Sight con-
sists of a collection of high contrast items, such as white
shapes against a black background, and black and white
plates and bowls. Most investigators use this kit to teach
patients how to detect high contrast items of different
shapes and configurations, and have found it useful and
effective. Some investigators have added items such as
cups of intermediate contrast (i.e. grey), canned foods,
and medicine bottles. Patients who have used an in-
home, scaled-down version of the kit have also reported
on its utility. Overall, the investigators placed emphasis
on working with objects that would help a patient im-
prove functionality in their everyday lives. In some situa-
tions where patients have been unable to return to the
clinic for regular rehabilitation visits, investigators have
traveled to patients’ homes and report that patients have
appreciated being able to work on aspects of visual func-
tion that are important for their day-to-day lives, such as
seeing objects in their homes, or being able to go out
and navigate in their neighborhoods. Working within
the context of a familiar environment may also have a
positive effect on a patient’s level of engagement and
motivation. If the patient is employed, skills learned can
also be incorporated into the work setting.
There are several device-related issues that may make
the rehabilitation process more challenging. First, device
fatigue and oversaturation may cause periods when hav-
ing the device turned on is not useful. Second, patients
can experience adaptation to the electrical stimulation,
and as a result, percepts can get dimmer after extended
device use. Third, new visual inputs from the Argus II
system may be difficult to initially interpret. A major
challenge of rehabilitation is determining how to inte-
grate these new visual sensations with a patient’s low vi-
sion and blindness skills. It was suggested that an
optimal strategy may be to teach patients to retain their
existing blindness skills such as auditory and tactile
function, and to supplement these with the vision pro-
vided by the Argus II.
In addition to their critical role in teaching patients
how to optimally use and integrate their new visual in-
puts into their daily lives, the investigators felt that re-
habilitation specialists could also make important
contributions to evaluating potential patients, both in
terms of looking for possible barriers to successful re-
habilitation, and managing the expectations of patients
and their families as to the degree of vision the patient
will experience. Pre-surgical interactions with the re-
habilitation specialist on the team would also help to
build interpersonal relationships that could facilitate the
rehabilitation process, and the specialist could also stress
the importance of coaching at home and family
participation.
Conclusion
The gathering of retinal surgeons, device program-
mers, rehabilitation specialists, and industry represen-
tatives allowed a comprehensive review of the Argus
II implantation and rehabilitation process. Early ex-
perience with the Argus II implant has delivered
promising results and highlighted new challenges. The
meeting of investigators from around the world also
allowed the coordination of future research efforts. A
collaborative listserve will be established and several
interesting topics of further study were identified.
These included the examination of longitudinal
changes in electrical thresholds in implanted patients,
the study of cross-modal activity on brain MRI as a
marker for Argus II function, the potential for retinal
recordings directly from the electrode array, and the
feasibility of implantation for age-related macular de-
generation. The present time represents a critical
juncture for retinal prosthetic systems- an opportunity
to make adjustments in techniques and procedures
that will drive future outcomes.
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